E-7820

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameE-7820
Drug Alias NameER-68203-00NSC-719239E-7820
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionIntegrin alpha-2 antagonists
TargetsIntegrin alpha-2
Therapy Area/IndicationsSolid tumoursMyelodysplastic SyndromesRectal Neoplasms +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesUkraine +[10] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesEisai Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesEisai Inc
Inactive CompaniesN/A
Active IndicationsMyelodysplastic SyndromesLeukemia, Myelomonocytic, ChronicLeukemia, Myeloid, Acute
Inactive IndicationsSolid tumoursRectal NeoplasmsColonic Neoplasms +[6] 

Other Information

ATC CodeN/A
Related LinksN/A